vs
徕博科（LH）与新闻集团（NWSA）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是新闻集团的1.5倍（$3.5B vs $2.4B），新闻集团净利率更高（8.2% vs 4.7%，领先3.5%），徕博科同比增速更快（5.6% vs 5.5%），徕博科自由现金流更多（$490.3M vs $132.0M），过去两年徕博科的营收复合增速更高（5.2% vs -1.3%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
新闻集团是全球知名的媒体集团，旗下拥有报纸、出版、数字媒体等多项媒体业务，在全球传媒领域拥有广泛影响力，专注于为受众提供及时多元的时事资讯与内容服务。
LH vs NWSA — 直观对比
营收规模更大
LH
是对方的1.5倍
$2.4B
营收增速更快
LH
高出0.1%
5.5%
净利率更高
NWSA
高出3.5%
4.7%
自由现金流更多
LH
多$358.3M
$132.0M
两年增速更快
LH
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $2.4B |
| 净利润 | $164.7M | $193.0M |
| 毛利率 | 28.2% | — |
| 营业利润率 | 7.6% | — |
| 净利率 | 4.7% | 8.2% |
| 营收同比 | 5.6% | 5.5% |
| 净利润同比 | 14.9% | -10.2% |
| 每股收益（稀释后） | $1.98 | $0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHNWSA
| Q4 25 | $3.5B | $2.4B | ||
| Q3 25 | $3.6B | $2.1B | ||
| Q2 25 | $3.5B | $1.6B | ||
| Q1 25 | $3.3B | $2.0B | ||
| Q4 24 | $3.3B | $2.2B | ||
| Q3 24 | $3.3B | $2.6B | ||
| Q2 24 | $3.2B | $2.6B | ||
| Q1 24 | $3.2B | $2.4B |
净利润LHNWSA
| Q4 25 | $164.7M | $193.0M | ||
| Q3 25 | $261.1M | $112.0M | ||
| Q2 25 | $237.9M | $743.0M | ||
| Q1 25 | $212.8M | $103.0M | ||
| Q4 24 | $143.4M | $215.0M | ||
| Q3 24 | $169.3M | $119.0M | ||
| Q2 24 | $205.3M | $50.0M | ||
| Q1 24 | $228.0M | $30.0M |
毛利率LHNWSA
| Q4 25 | 28.2% | — | ||
| Q3 25 | 28.8% | — | ||
| Q2 25 | 29.7% | — | ||
| Q1 25 | 28.3% | — | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 27.6% | — | ||
| Q2 24 | 28.8% | — | ||
| Q1 24 | 28.2% | — |
营业利润率LHNWSA
| Q4 25 | 7.6% | — | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 11.2% | 8.5% | ||
| Q1 25 | 9.7% | 7.5% | ||
| Q4 24 | 6.5% | 19.2% | ||
| Q3 24 | 7.7% | 7.9% | ||
| Q2 24 | 9.2% | 4.3% | ||
| Q1 24 | 10.1% | 2.6% |
净利率LHNWSA
| Q4 25 | 4.7% | 8.2% | ||
| Q3 25 | 7.3% | 5.2% | ||
| Q2 25 | 6.7% | 45.6% | ||
| Q1 25 | 6.4% | 5.1% | ||
| Q4 24 | 4.3% | 9.6% | ||
| Q3 24 | 5.2% | 4.6% | ||
| Q2 24 | 6.4% | 1.9% | ||
| Q1 24 | 7.2% | 1.2% |
每股收益（稀释后）LHNWSA
| Q4 25 | $1.98 | $0.34 | ||
| Q3 25 | $3.12 | $0.20 | ||
| Q2 25 | $2.84 | $1.30 | ||
| Q1 25 | $2.52 | $0.18 | ||
| Q4 24 | $1.72 | $0.38 | ||
| Q3 24 | $2.00 | $0.21 | ||
| Q2 24 | $2.43 | $0.09 | ||
| Q1 24 | $2.69 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $2.1B |
| 总债务越低越好 | — | $2.0B |
| 股东权益账面价值 | $8.6B | $8.8B |
| 总资产 | $18.4B | $15.5B |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资LHNWSA
| Q4 25 | $532.3M | $2.1B | ||
| Q3 25 | $598.1M | $2.2B | ||
| Q2 25 | $647.3M | $2.4B | ||
| Q1 25 | $369.4M | $2.1B | ||
| Q4 24 | $1.5B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $265.1M | $2.0B | ||
| Q1 24 | $99.3M | $1.9B |
总债务LHNWSA
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.9B |
股东权益LHNWSA
| Q4 25 | $8.6B | $8.8B | ||
| Q3 25 | $8.7B | $8.7B | ||
| Q2 25 | $8.5B | $8.8B | ||
| Q1 25 | $8.3B | $8.2B | ||
| Q4 24 | $8.1B | $8.1B | ||
| Q3 24 | $8.2B | $8.3B | ||
| Q2 24 | $8.0B | $8.1B | ||
| Q1 24 | $8.0B | $8.1B |
总资产LHNWSA
| Q4 25 | $18.4B | $15.5B | ||
| Q3 25 | $18.3B | $15.3B | ||
| Q2 25 | $18.1B | $15.5B | ||
| Q1 25 | $17.6B | $16.6B | ||
| Q4 24 | $18.4B | $16.2B | ||
| Q3 24 | $18.6B | $16.9B | ||
| Q2 24 | $16.7B | $16.7B | ||
| Q1 24 | $16.5B | $16.5B |
负债/权益比LHNWSA
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.36× | ||
| Q1 24 | — | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $231.0M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $132.0M |
| 自由现金流率自由现金流/营收 | 13.9% | 5.6% |
| 资本支出强度资本支出/营收 | 3.5% | 4.2% |
| 现金转化率经营现金流/净利润 | 3.73× | 1.20× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $586.0M |
8季度趋势，按日历期对齐
经营现金流LHNWSA
| Q4 25 | $614.2M | $231.0M | ||
| Q3 25 | $387.2M | $85.0M | ||
| Q2 25 | $620.6M | $189.0M | ||
| Q1 25 | $18.5M | $511.0M | ||
| Q4 24 | $777.2M | $252.0M | ||
| Q3 24 | $277.3M | $64.0M | ||
| Q2 24 | $561.1M | $254.0M | ||
| Q1 24 | $-29.8M | $539.0M |
自由现金流LHNWSA
| Q4 25 | $490.3M | $132.0M | ||
| Q3 25 | $280.5M | $4.0M | ||
| Q2 25 | $542.7M | $32.0M | ||
| Q1 25 | $-107.5M | $418.0M | ||
| Q4 24 | $665.1M | $190.0M | ||
| Q3 24 | $161.5M | $-31.0M | ||
| Q2 24 | $432.9M | $111.0M | ||
| Q1 24 | $-163.6M | $422.0M |
自由现金流率LHNWSA
| Q4 25 | 13.9% | 5.6% | ||
| Q3 25 | 7.9% | 0.2% | ||
| Q2 25 | 15.4% | 2.0% | ||
| Q1 25 | -3.2% | 20.8% | ||
| Q4 24 | 20.0% | 8.5% | ||
| Q3 24 | 4.9% | -1.2% | ||
| Q2 24 | 13.4% | 4.3% | ||
| Q1 24 | -5.2% | 17.4% |
资本支出强度LHNWSA
| Q4 25 | 3.5% | 4.2% | ||
| Q3 25 | 3.0% | 3.8% | ||
| Q2 25 | 2.2% | 9.6% | ||
| Q1 25 | 3.8% | 4.6% | ||
| Q4 24 | 3.4% | 2.8% | ||
| Q3 24 | 3.5% | 3.7% | ||
| Q2 24 | 4.0% | 5.5% | ||
| Q1 24 | 4.2% | 4.8% |
现金转化率LHNWSA
| Q4 25 | 3.73× | 1.20× | ||
| Q3 25 | 1.48× | 0.76× | ||
| Q2 25 | 2.61× | 0.25× | ||
| Q1 25 | 0.09× | 4.96× | ||
| Q4 24 | 5.42× | 1.17× | ||
| Q3 24 | 1.64× | 0.54× | ||
| Q2 24 | 2.73× | 5.08× | ||
| Q1 24 | -0.13× | 17.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
NWSA
| Book Publishing Segment | $633.0M | 27% |
| Consumer | $607.0M | 26% |
| News And Information Services Segment | $570.0M | 24% |
| Real Estate | $401.0M | 17% |
| Other Product Or Service | $173.0M | 7% |
